Glympse Bio

Glympse Bio's platform uses injectable nanoparticles that release synthetic biomarkers in response to disease-specific protease activity. These biomarkers are collected in urine and analyzed by a mass spectrometer, with machine learning algorithms interpreting the pattern to produce a disease signature.

Glympse Bio raised a $46 million Series A round in 2019 co-led by Andreessen Horowitz and Data Collective, with participation from Polaris Partners, Lifeforce Capital, and other venture firms (per the company's announcement, 2019). The company has not disclosed additional financing rounds.

Glympse Bio initially focused on non-alcoholic steatohepatitis (NASH), a form of liver disease. In 2021, the company announced a collaboration with the National Cancer Institute to expand into oncology applications. Its platform is designed to be programmable for multiple diseases, including fibrotic conditions and cancer.

Glympse Bio is a privately held biotechnology company. It has not filed for an initial public offering and remains backed by venture capital investors.

Glympse Bio's technology originated from the laboratory of Sangeeta Bhatia, a professor at MIT and a core institute member at the Wyss Institute for Biologically Inspired Engineering. The company's diagnostic platform builds on research in synthetic biomarkers and nanoparticles published in peer-reviewed journals.

Glympse Bio's platform measures real-time enzymatic activity in the body, unlike conventional diagnostics that detect static biomarkers. This activity-based approach could allow earlier detection of disease progression and therapy response, particularly for chronic diseases like NASH where non-invasive monitoring options are limited.